- Home
- PLG vs ORMP Comparison
PLG vs ORMP Comparison
Compare PLG & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLG | ORMP |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.1M | 197.6M |
| IPO Year | 2002 | 2010 |
Fundamental Metrics
Financial Performance| Metric | PLG | ORMP |
|---|---|---|
| Price | $1.30 | $4.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 880.7K | 133.9K |
| Earning Date | 11-25-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 5.95% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.52 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $1.18 | $2.09 |
| 52 Week High | $4.04 | $5.47 |
Technical Indicators
Market Signals| Indicator | PLG | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 30.56 |
| Support Level | $1.18 | $4.16 |
| Resistance Level | $1.47 | $4.22 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 14.29 | 5.41 |
Price Performance
Historical ComparisonAbout PLG Platinum Group Metals Ltd. (Canada)
Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.